Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

DSpace/Manakin Repository

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
 
Franken, M. G.; Leeneman, B.; Aarts, M. J.B.; van Akkooi, A. C.J.; van den Berkmortel, F. W.P.J.; Boers-Sonderen, M. J.; van den Eertwegh, A. J.M.; de Groot, J. W.B.; Hospers, G. A.P.; Kapiteijn, E.; Piersma, D.; van Rijn, R. S.; Suijkerbuijk, K. P.M.; van der Veldt, A. A.M.; Westgeest, H. M.; Wouters, M. W.J.M.; Haanen, J. B.A.G.; Uyl-de Groot, C. A.
(2021) ESMO open, volume 6, issue 6
(Article)
Abstract
Background: The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs. Materials and methods: Data on survival and health care resource use were retrieved from the Dutch Melanoma Treatment Registry. The Kaplan–Meier method was ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: costs, immunotherapeutic drugs, melanoma, survival, targeted drugs, Oncology, Cancer Research
DOI: https://doi.org/10.1016/j.esmoop.2021.100320
ISSN: 2059-7029
Publisher: BMJ Publishing Group
Note: Funding Information: The Dutch Melanoma Treatment Registry received a start-up grant from The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). Data collection for the DMTR is funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Pierre Fabre. Roche ceased funding in 2019 and Pierre Fabre started funding in 2019. Funding Information: No funding was obtained for this manuscript. The Dutch Melanoma Treatment Registry received a start-up grant from The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). Data collection for the DMTR is funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Pierre Fabre. Roche ceased funding in 2019 and Pierre Fabre started funding in 2019. ACJvA reports grants and personal fees from Amgen and Merck-Pfizer; and personal fees from Bristol-Myers Squibb, Novartis, MSD-Merck, Pierre Fabre, Sanofi, and 4SC, outside the submitted work. AJMvdE reports personal fees from BMS, MSD, Merck, Sanofi, Roche, Novartis, Eisai, Ipsen, Pfizer, and Pierre Fabre; and grants from Grant for clinical studies, outside the submitted work. MGF reports grants from Roche Nederland B.V. Daiichi Sankyo, Abbvie, Gilead Sciences Netherlands BV, and Astellas Pharma BV, outside the submitted work. JWBdG reports personal fees from BMS, MSD, Pierre Fabre, and Servier, outside the submitted work. JBAGH reports grants and other from BMS, MSD, Novartis, BioNTech, and Amgen; other from Achilles Tx, GSK, Immunocore, Ipsen, Merck Serono, Molecular Partners, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, and Vaximm; and personal fees from Neogene Tx, outside the submitted work. GAPH reports consulting and advisory role: Amgen, Roche, MSD, BMS, Pfizer, Novartis, Pierre Fabry, paid to the institution (UMCG); and research grant from BMS and Seerave, paid to the institution (UMCG). DP reports personal fees from BMS advisory board and Pierre Fabre advisory board, outside the submitted work. KPMS reports personal fees from Novartis, Roche, Pierre Fabre, MSD, BMS, and Abbvie, outside the submitted work. AAMvdV reports other from BMS, MSD, Merck, Sanofi, Roche, Novartis, Eisai, Ipsen, Pfizer, and Pierre Fabre, outside the submitted work. HMW reports non-financial support from Ipsen; personal fees from Roche; and personal fees and non-financial support from Astellas, outside the submitted work. All other authors have declared no conflicts of interest. Funding Information: ACJvA reports grants and personal fees from Amgen and Merck-Pfizer; and personal fees from Bristol-Myers Squibb, Novartis, MSD-Merck, Pierre Fabre, Sanofi, and 4SC, outside the submitted work. AJMvdE reports personal fees from BMS, MSD, Merck, Sanofi, Roche, Novartis, Eisai, Ipsen, Pfizer, and Pierre Fabre; and grants from Grant for clinical studies, outside the submitted work. MGF reports grants from Roche Nederland B.V., Daiichi Sankyo, Abbvie, Gilead Sciences Netherlands BV, and Astellas Pharma BV, outside the submitted work. JWBdG reports personal fees from BMS, MSD, Pierre Fabre, and Servier, outside the submitted work. JBAGH reports grants and other from BMS, MSD, Novartis, BioNTech, and Amgen; other from Achilles Tx, GSK, Immunocore, Ipsen, Merck Serono, Molecular Partners, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, and Vaximm; and personal fees from Neogene Tx, outside the submitted work. GAPH reports consulting and advisory role: Amgen, Roche, MSD, BMS, Pfizer, Novartis, Pierre Fabry, paid to the institution (UMCG); and research grant from BMS and Seerave, paid to the institution (UMCG). DP reports personal fees from BMS advisory board and Pierre Fabre advisory board, outside the submitted work. KPMS reports personal fees from Novartis, Roche, Pierre Fabre, MSD, BMS, and Abbvie, outside the submitted work. AAMvdV reports other from BMS, MSD, Merck, Sanofi, Roche, Novartis, Eisai, Ipsen, Pfizer, and Pierre Fabre, outside the submitted work. HMW reports non-financial support from Ipsen; personal fees from Roche; and personal fees and non-financial support from Astellas, outside the submitted work. All other authors have declared no conflicts of interest. Publisher Copyright: © 2021 The Author(s)
(Peer reviewed)